Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 77

1.

Detection of rapalog-mediated therapeutic response in renal cancer xenografts using ⁶⁴Cu-bevacizumab immunoPET.

Chang AJ, Sohn R, Lu ZH, Arbeit JM, Lapi SE.

PLoS One. 2013;8(3):e58949. doi: 10.1371/journal.pone.0058949. Epub 2013 Mar 14.

2.

PET imaging of tumor angiogenesis in mice with VEGF-A-targeted (86)Y-CHX-A″-DTPA-bevacizumab.

Nayak TK, Garmestani K, Baidoo KE, Milenic DE, Brechbiel MW.

Int J Cancer. 2011 Feb 15;128(4):920-6. doi: 10.1002/ijc.25409.

3.

Measurement of tumor VEGF-A levels with 89Zr-bevacizumab PET as an early biomarker for the antiangiogenic effect of everolimus treatment in an ovarian cancer xenograft model.

van der Bilt AR, Terwisscha van Scheltinga AG, Timmer-Bosscha H, Schröder CP, Pot L, Kosterink JG, van der Zee AG, Lub-de Hooge MN, de Jong S, de Vries EG, Reyners AK.

Clin Cancer Res. 2012 Nov 15;18(22):6306-14. doi: 10.1158/1078-0432.CCR-12-0406. Epub 2012 Sep 26.

4.

Positron emission tomography imaging and biodistribution of vascular endothelial growth factor with 64Cu-labeled bevacizumab in colorectal cancer xenografts.

Paudyal B, Paudyal P, Oriuchi N, Hanaoka H, Tominaga H, Endo K.

Cancer Sci. 2011 Jan;102(1):117-21. doi: 10.1111/j.1349-7006.2010.01763.x. Epub 2010 Nov 10.

5.

In vivo characterization of 68Ga-NOTA-VEGF 121 for the imaging of VEGF receptor expression in U87MG tumor xenograft models.

Kang CM, Kim SM, Koo HJ, Yim MS, Lee KH, Ryu EK, Choe YS.

Eur J Nucl Med Mol Imaging. 2013 Jan;40(2):198-206. doi: 10.1007/s00259-012-2266-x. Epub 2012 Oct 25.

PMID:
23096079
6.

PET of vascular endothelial growth factor receptor expression.

Cai W, Chen K, Mohamedali KA, Cao Q, Gambhir SS, Rosenblum MG, Chen X.

J Nucl Med. 2006 Dec;47(12):2048-56.

7.

89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922.

Nagengast WB, de Korte MA, Oude Munnink TH, Timmer-Bosscha H, den Dunnen WF, Hollema H, de Jong JR, Jensen MR, Quadt C, Garcia-Echeverria C, van Dongen GA, Lub-de Hooge MN, Schröder CP, de Vries EG.

J Nucl Med. 2010 May;51(5):761-7. doi: 10.2967/jnumed.109.071043. Epub 2010 Apr 15.

8.

Quantitative PET imaging of VEGF receptor expression.

Chen K, Cai W, Li ZB, Wang H, Chen X.

Mol Imaging Biol. 2009 Jan-Feb;11(1):15-22. doi: 10.1007/s11307-008-0172-1. Epub 2008 Sep 11.

PMID:
18784964
9.

89Zr-bevacizumab PET imaging in primary breast cancer.

Gaykema SB, Brouwers AH, Lub-de Hooge MN, Pleijhuis RG, Timmer-Bosscha H, Pot L, van Dam GM, van der Meulen SB, de Jong JR, Bart J, de Vries J, Jansen L, de Vries EG, Schröder CP.

J Nucl Med. 2013 Jul;54(7):1014-8. doi: 10.2967/jnumed.112.117218. Epub 2013 May 7.

10.

Novel radiolabeled peptides for breast and prostate tumor PET imaging: (64)Cu/and (68)Ga/NOTA-PEG-[D-Tyr(6),βAla(11),Thi(13),Nle(14)]BBN(6-14).

Fournier P, Dumulon-Perreault V, Ait-Mohand S, Tremblay S, Bénard F, Lecomte R, Guérin B.

Bioconjug Chem. 2012 Aug 15;23(8):1687-93. doi: 10.1021/bc3002437. Epub 2012 Jul 25.

PMID:
22770480
11.

Everolimus Reduces (89)Zr-Bevacizumab Tumor Uptake in Patients with Neuroendocrine Tumors.

van Asselt SJ, Oosting SF, Brouwers AH, Bongaerts AH, de Jong JR, Lub-de Hooge MN, Oude Munnink TH, Fiebrich HB, Sluiter WJ, Links TP, Walenkamp AM, de Vries EG.

J Nucl Med. 2014 Jul;55(7):1087-92. doi: 10.2967/jnumed.113.129056. Epub 2014 May 1.

12.

111In-bevacizumab imaging of renal cell cancer and evaluation of neoadjuvant treatment with the vascular endothelial growth factor receptor inhibitor sorafenib.

Desar IM, Stillebroer AB, Oosterwijk E, Leenders WP, van Herpen CM, van der Graaf WT, Boerman OC, Mulders PF, Oyen WJ.

J Nucl Med. 2010 Nov;51(11):1707-15. doi: 10.2967/jnumed.110.078030. Epub 2010 Oct 18.

13.

Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma.

Krajewski KM, Guo M, Van den Abbeele AD, Yap J, Ramaiya N, Jagannathan J, Heng DY, Atkins MB, McDermott DF, Schutz FA, Pedrosa I, Choueiri TK.

Eur Urol. 2011 May;59(5):856-62. doi: 10.1016/j.eururo.2011.01.038. Epub 2011 Feb 1.

PMID:
21306819
14.

ScVEGF-PEG-HBED-CC and scVEGF-PEG-NOTA conjugates: comparison of easy-to-label recombinant proteins for [68Ga]PET imaging of VEGF receptors in angiogenic vasculature.

Eder M, Krivoshein AV, Backer M, Backer JM, Haberkorn U, Eisenhut M.

Nucl Med Biol. 2010 May;37(4):405-12. doi: 10.1016/j.nucmedbio.2010.02.001. Epub 2010 Apr 7.

PMID:
20447550
15.

Biomarkers for antitumor activity of bevacizumab in gastric cancer models.

Yamashita-Kashima Y, Fujimoto-Ouchi K, Yorozu K, Kurasawa M, Yanagisawa M, Yasuno H, Mori K.

BMC Cancer. 2012 Jan 25;12:37. doi: 10.1186/1471-2407-12-37.

16.

Small-animal PET of tumors with (64)Cu-labeled RGD-bombesin heterodimer.

Liu Z, Li ZB, Cao Q, Liu S, Wang F, Chen X.

J Nucl Med. 2009 Jul;50(7):1168-77. doi: 10.2967/jnumed.108.061739. Epub 2009 Jun 12.

17.

Integration of novel agents in the treatment of colorectal cancer.

Iqbal S, Lenz HJ.

Cancer Chemother Pharmacol. 2004 Sep;54 Suppl 1:S32-9. Review.

PMID:
15309512
18.

Circulating vascular endothelial growth factor receptor 2/pAkt-positive cells as a functional pharmacodynamic marker in metastatic colorectal cancers treated with antiangiogenic agent.

Shin SJ, Hwang JW, Ahn JB, Rha SY, Roh JK, Chung HC.

Invest New Drugs. 2013 Feb;31(1):1-13. doi: 10.1007/s10637-012-9817-7. Epub 2012 Apr 27.

PMID:
22539090
19.

Vascular disruption in combination with mTOR inhibition in renal cell carcinoma.

Ellis L, Shah P, Hammers H, Lehet K, Sotomayor P, Azabdaftari G, Seshadri M, Pili R.

Mol Cancer Ther. 2012 Feb;11(2):383-92. doi: 10.1158/1535-7163.MCT-11-0748. Epub 2011 Nov 14.

20.

Tumor accumulation of radiolabeled bevacizumab due to targeting of cell- and matrix-associated VEGF-A isoforms.

Stollman TH, Scheer MG, Franssen GM, Verrijp KN, Oyen WJ, Ruers TJ, Leenders WP, Boerman OC.

Cancer Biother Radiopharm. 2009 Apr;24(2):195-200. doi: 10.1089/cbr.2008.0574.

PMID:
19409041
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk